Galera claims pos­i­tive up­date in pan­cre­at­ic can­cer but does­n't re­port p-val­ues; Am­gen launch­es Cana­di­an fund in tan­dem with CCRM

Malvern, PA-based Galera Ther­a­peu­tics re­leased up­dat­ed fol­low-up da­ta Wednes­day af­ter­noon for a Phase I/II tri­al in pan­cre­at­ic can­cer, though it did …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.